Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Argo Graphene Advances Refinery Strategy and Reports Promising Industrial Lubricant Testing ResultsArgo Graphene (OTC: ARLSF) establishing commercial-scale graphene refinery in Chicago and evaluating graphene as industrial lubricant performance-enhancing
- Greenland Energy CompanyGreenland Energy Company Announces the Resignation of Roderick McIllree From the Board of DirectorsGreenland Energy Company (NASDAQ: GLND) ("the Company" or "Greenland Energy"), an oil exploration company focused on East Greenland's Jameson Land Basin, today announced Roderick McIllree's resignation from the Company's Board of Directors (the...
- ExxonMobilExxonMobil to Release Third Quarter 2026 Financial ResultsCompanies: ExxonMobilSPRING, Texas--ExxonMobil Holdings Corporation (NYSE: XOM) will release its third quarter 2026 financial results on Friday, October 30, 2026. The company will issue a press release via Business Wire that will be available at 5:30 a.m. CT at investor.exxonmobil.com . Darren Woods, Chairman and Chief Executive Officer; Neil Hansen, Senior Vice President and Chief Financial Officer; and Jim Chapman, Vi
- Delta Air LinesDelta Air Lines announces September quarter 2026 financial resultsCompanies: Delta Air LinesDelta Air Lines (NYSE: DAL) today reported financial results for the September quarter and provided its outlook for the December quarter and full year 2026. “Demand remains strong, supported by consumers’ growing preference for experiences and travel, with air travel continuing to be one of the best values in the consumer economy," said Ed Bastian, Delta's Chief Executive Officer. "Against this backdrop, we delivered September quarter pre-tax profit of $1.5 billion, matching last year's performance, and generated $1.9 billion of free cash flow year-to-date. Our resilience reflects the structural durability we’ve built over many years, enabling us to effectively navigate one of the most elevated fuel environments in recent times. The foundation of that resilience is our people, whose commitment to delivering for our customers continues to set Delta apart." Bastian continued, "For the full year, we expect to generate a pre-tax profit of roughly $4.5 billion, absorbing a $6 billion increase in fuel costs. Looking ahead, our focus remains on profitable growth and delivering against our long-term financial framework, including mid-teens margins and returns, durable free cash flow and gross leverage of approximately one times." September Quarter 2026 GAAP Financial Results Operating revenue of $20.2 billion Operating income of $1.5 billion with an operating margin of 7.2% Pre-tax income of $1.1 billion with a pre-tax margin of 5.3% Earnings per share of $1.15 Operating cash flow of $1.7 billion September Quarter 2026 Non-GAAP Financial Results Operating revenue of $17.6 billion Operating income of $1.7 billion with an operating margin of 9.4% Pre-tax income of $1.5 billion with a pre-tax margin of 8.5% Earnings per share of $1.72 Operating cash flow of $1.7 billion Read the full release on PR Newswire via download. Forward Looking Statements Statements made in this press release that are not historical facts, including statements regarding our estimates, expectations, beliefs, intentions, projections, goals, aspirations, commitments or strategies for the future, should be considered “forward-looking statements” under the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees or promised outcomes and should not be construed as such. All forward-looking statements involve a number of risks and uncertainties that could cause actual results to differ materially from the estimates, expectations, beliefs, intentions, projections, goals, aspirations, commitments and strategies reflected in or suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to, the possible effects of serious accidents involving our aircraft or aircraft of our airline partners; breaches or lapses in the security of technology systems we use and rely on, which could compromise the data stored within them, as well as failure to comply with evolving global privacy and security regulatory obligations or adequately address increasing customer focus on privacy issues and data security; disruptions in our information technology infrastructure; failure of the technology we use or depend on to perform effectively, including new and emerging technologies; increases in the price of aircraft fuel; extended disruptions in the supply of aircraft fuel, including from Monroe Energy, LLC (“Monroe”), our wholly-owned subsidiary that operates the Trainer refinery; failure to achieve expected results or returns from our commercial relationships with airlines in other parts of the world and the investments we have in certain of those airlines; the effects of a significant disruption in the operations or performance of third parties on which we rely; failure to comply with the financial or other covenants in our financing agreements; labor-related disruptions; the effects on our business of seasonality and other factors beyond our control, such as changes in value in our equity investments, severe weather conditions, natural disasters or other environmental events, including from the impact of climate change; failure or inability of insurance to cover a significant liability at Monroe’s refinery; failure to comply with existing and future environmental regulations to which Monroe’s refinery operations are subject, including those relating to the discharge of materials into the environment, waste management, pollution prevention measures and greenhouse gas emissions; significant damage to our reputation and brand, including from exposure to significant adverse publicity or inability to achieve certain sustainability goals; our ability to retain senior management and other key employees, and to maintain our company culture; disease outbreaks or other public health threats, and measures implemented to combat them; the effects of terrorist attacks, geopolitical conflict or security events; competitive conditions in the airline industry; extended interruptions or disruptions in service at major airports where we operate; significant problems associated with types of aircraft or engines we operate; the effects of extensive regulatory and legal compliance requirements we are subject to; the impact of laws and regulations governing environmental protection, including but not limited to regulation of hazardous substances, increased regulation to reduce emissions and other risks associated with climate change, and the cost of compliance with more stringent environmental regulations; and unfavorable economic or political conditions in the markets in which we operate or volatility in currency exchange rates. Additional information concerning risks and uncertainties that could cause differences between actual results and forward-looking statements is contained in our Securities and Exchange Commission (SEC) filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and other filings filed with the SEC from time to time. Caution should be taken not to place undue reliance on our forward-looking statements, which represent our views only as of the date of this press release, and which we undertake no obligation to update except to the extent required by law.
- BayerU.S. FDA approves finerenone for new indication in patients with chronic kidney disease associated with type 1 diabetesCompanies: BayerBayer announced today that the U.S. Food and Drug Administration (FDA) has approved Kerendia™ (finerenone), a selective, non-steroidal mineralocorticoid receptor antagonist (nsMRA), for the treatment of adult patients with chronic kidney disease (CKD) associated with type 1 diabetes (T1D). Finerenone (10mg, 20mg) is now indicated to reduce urinary albumin-to-creatinine ratio (UACR), which is expected to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline and end-stage kidney disease in adults with chronic kidney disease associated with type 1 diabetes. Approximately 30% of people with type 1 diabetes in the U.S. develop chronic kidney disease, increasing their risk of kidney failure and cardiovascular events. Even with recommended treatments for blood glucose and blood pressure management, many patients remain at risk of kidney disease progression and cardiovascular complications. “For more than three decades, people with chronic kidney disease and type 1 diabetes have had limited options to address the risk of kidney disease progression," said Dr. Janet McGill, Professor of Medicine in the Division of Endocrinology, Metabolism, and Lipid Research at Washington University School of Medicine in St. Louis, and Co-Chair of the study’s Executive Committee. "The approval of Kerendia to reduce UACR, which is expected to slow chronic kidney disease progression in adults with type 1 diabetes, provides an important new treatment option for a population that has continued to face substantial unmet need.” “Today’s approval in the U.S. marks an important advance for people living with chronic kidney disease associated with type 1 diabetes—a serious and often under-recognized condition. As the first new FDA-approved treatment option in more than 30 years for this patient population, Kerendia reflects Bayer’s commitment to addressing significant unmet needs and bringing meaningful new treatment options to patients,” said Christine Roth Executive Vice President, Global Product Strategy and Commercialization and Member of the Pharmaceuticals Leadership Team at Bayer. In May 2026, the FDA granted Priority Review designation for Bayer’s supplemental New Drug Application for finerenone for the treatment of adult patients with CKD associated with T1D. The approval of finerenone by the FDA is based on the positive results of the Phase III FINE-ONE study, which were published in the New England Journal of Medicine in March 2026 and presented in November 2025 as “Featured High-Impact Clinical Trial” during the Opening Plenary session of the American Society of Nephrology’s (ASN) Kidney Week. These findings are supported by pooled analyses from the Phase III FIDELIO-DKD and FIGARO-DKD studies in CKD associated with type 2 diabetes (T2D), showing that more than 80% of finerenone's kidney benefit was explained by reductions in UACR. In the U.S., Kerendia has been approved since 2021 for the treatment of adult patients with CKD associated with type 2 diabetes (T2D), since 2025 for the treatment of adult patients with symptomatic chronic heart failure with left ventricular ejection fraction (LVEF) ≥ 40%, and now for the treatment of adult patients with CKD associated with type 1 diabetes. About Kerendia™ / Firialta™ (finerenone) Kerendia™ and Firialta™ are globally protected trademarks for finerenone. Finerenone is a selective, non-steroidal mineralocorticoid receptor antagonist (nsMRA) that has been shown to block harmful effects of MR overactivation. MR overactivation contributes to chronic kidney disease (CKD) progression and cardiovascular damage which can be driven by metabolic, hemodynamic, or inflammatory and fibrotic factors. Finerenone so far has been studied in more than 20,000 patients across multiple populations with chronic kidney disease and/or heart failure. Finerenone is the first drug targeting the MR pathway that in five pivotal Phase III studies has demonstrated clinically proven heart and/or kidney benefits across a broad range of patient populations, for patients with HF LVEF ≥40%, CKD associated with T2D, CKD associated with T1D, and CKD without diabetes. Since 2021, finerenone is marketed as Kerendia™ or, in selected countries, as Firialta™, and approved for the treatment of adult patients with CKD associated with type 2 diabetes (T2D) in more than 100 countries worldwide, including in China, Europe, Japan, and the U.S. Finerenone is also approved for the treatment of heart failure with LVEF ≥ 40% in the U.S., Europe, Japan, China, and several other markets. Applications for marketing authorization of finerenone in non-diabetic CKD have been filed in China and Japan; so far, finerenone is not approved in non-diabetic CKD in any country worldwide. With the new approval by the FDA, the U.S. are the only country where Kerendia is approved for the treatment of adult patients with CKD associated with type 1 diabetes. About FINE-ONE In FINE-ONE, 242 participants were randomized from more than 80 sites across 9 countries worldwide to receive either finerenone or placebo once daily. In addition, patients in the study received usual therapy to treat symptoms and comorbidities. FINE-ONE is a global, randomized, placebo-controlled, double-blind, multicenter Phase III study in people with CKD and T1D. In FINE-ONE, finerenone in addition to standard of care significantly reduced the primary endpoint of relative change in urine albumin-to-creatinine ratio, or UACR, by 25% over six months compared with placebo. At Month 3 and at Month 6, UACR reduction with finerenone was 22%, and 28%, respectively, compared to placebo. At any time following baseline, 68.1% of participants receiving finerenone achieved a reduction in UACR of at least 30%, compared with 46.6% receiving placebo. A reduction in UACR of 30% is a threshold established by the American Diabetes Association (ADA) as being associated with slower CKD progression in patients with CKD associated with type 2 diabetes. Reductions in UACR of this magnitude have been shown in prior Phase III studies in adults with CKD and T2D to be associated with a delay in kidney disease progression and a reduction in cardiovascular events. The safety profile of finerenone in FINE-ONE was largely consistent with the existing body of evidence in adults with chronic kidney disease associated with type 2 diabetes. About Chronic Kidney Disease associated with Type 1 Diabetes Type 1 Diabetes (T1D) is a chronic autoimmune disorder characterized by destruction of pancreatic beta cells leading to insulin deficiency and requiring lifelong insulin treatment. Among the US population overall, crude estimates for 2018 indicated that 1.4 million adults aged 20 years or older (or 5.2% of all US adults with diagnosed diabetes), reported both having T1D and using insulin. CKD is a common and potentially deadly condition that is widely underrecognized. CKD progresses silently and unpredictably, with many symptoms not appearing until the disease is well-advanced. CKD is one of the most frequent complications arising from diabetes and is also an independent risk factor of cardiovascular disease. CKD affects approximately 30% of people with T1D. The 2017 global prevalence of CKD due to T1D was an estimated 32.5 per 100,000 individuals. The clinical course of CKD in people with T1D is characterized by an increased urinary albumin excretion rate, which is a first sign of kidney damage and may progress to macroalbuminuria and decrease in kidney function as measured by estimated glomerular filtration rate (eGFR). The treatment of T1D consists of insulin treatment to control hyperglycemia. In people with T1D, blood glucose intervention targeting HbA1c levels ≤7% can slow onset and progression of kidney disease. Despite guideline-recommended treatment with ACEIs and ARBs, residual risk remains high in people with CKD and T1D, with up to a quarter progressing to end-stage-kidney-disease. CKD associated with T1D significantly increases the risk of kidney failure and cardiovascular events, contributing to CKD being a leading cause of death in T1D. About Bayer’s Commitment in Cardiovascular, Kidney and Cerebrovascular Diseases Bayer is a leader in the area of cardiology and is advancing a portfolio of innovative treatments for cardiovascular, kidney and cerebrovascular diseases with high unmet medical needs. The company has set a clear focus on developing therapies to treat such diseases (e.g., heart failure, cardiomyopathies, chronic kidney disease, and stroke), and it is its ambition to take a leading role in the care of patients with these diseases. Bayer’s portfolio already includes several innovative products and compounds in various stages of preclinical and clinical development. Together, these products reflect the company’s approach to research, which prioritizes targets and pathways with the potential to impact the way that cardiovascular, kidney, and cerebrovascular diseases are diagnosed and treated. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros. For more information, go to www.bayer.com. Find more information at https://pharma.bayer.com Follow us on Facebook: http://www.facebook.com/bayer Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Bayer AG is a holding company with operating subsidiaries worldwide. References to “Bayer” or “the company” herein may refer to one or more subsidiaries as context requires.
- ExxonMobilExxonMobil: Announces Pricing Terms, Expiration and Results of its Cash Tender Offers for Outstanding 2030 1.900% Senior Notes and 2031 2.150% Senior NotesCompanies: ExxonMobilSPRING, Texas--ExxonMobil Holdings Corporation (" ExxonMobil ") (NYSE: XOM ) today announces the pricing terms, expiration and results of the offers to purchase for cash any and all of the outstanding $1,100,000,000 1.900% Senior Notes due 2030 (the “ 2030 Notes ”) and $1,000,000,000 2.150% Senior Notes due 2031 (the “ 2031 Notes ”, and together with the 2030 Notes, the “ Notes ”) of Pioneer Natural
- ExxonMobilExxonMobil: Cash Tender Offers for Outstanding 2030 1.900% Senior Notes and 2031 2.150% Senior NotesCompanies: ExxonMobilSPRING, Texas--ExxonMobil Holdings Corporation ("ExxonMobil") (NYSE: XOM ) today announces that its wholly owned subsidiary, Pioneer Natural Resources Company (the " Offeror ") is offering to purchase for cash any and all of its outstanding $1,100,000,000 1.900% Senior Notes due 2030 (the “ 2030 Notes ”) and $1,000,000,000 2.150% Senior Notes due 2031 (the “ 2031 Notes ”, and together with the 2030
- Hyundai Motor CompanyHyundai Motor Group Appoints Uni Hong as Head of HMG Energy&Hydrogen Business DivisionCompanies: Hyundai Motor CompanyGlobal energy expert from bp with extensive experience spanning upstream, downstream, trading, and diverse energy portfolios Expertise spans hydrogen, petroleum, LNG and renewable energy across resource development, supply chain structuring, and long-term partnerships Will drive advancement of hydrogen value chain across hydrogen production, storage, transportation, and refueling infrastructure Expected to enhance the Group's future energy business competitiveness and accelerate hydrogen ecosystem expansion leveraging global business experience and networks
- ExxonMobilExxonMobil to Speak at Barclays 40th Annual Energy-Power ConferenceCompanies: ExxonMobilSPRING, Texas--ExxonMobil Holdings Corporation (NYSE: XOM) today announced Neil Hansen, Senior Vice President and Chief Financial Officer, will conduct a fireside chat at the Barclays 40th Annual Energy-Power Conference in New York on September 9, 2026, at 8:00 a.m. ET. To access the live webcast, visit the event page . An archived audio portion of the webcast will be available on the ExxonMobil web
- ExxonMobilExxonMobil Announces Second-Quarter 2026 ResultsCompanies: ExxonMobilAdvantaged portfolio, integration, and structural savings support earnings and cash flow in volatile market Reported EPS of $3.48, or $3.52 adjusted EPS1 Highest Upstream production in more than two decades, excluding the Middle East disruptions2 Record Permian production, consistent with planned 9% CAGR through 2030, exceeding all competitors3 Fifth Guyana FPSO set sail with production startup on plan for 4Q26, incr
- ExxonMobilExxonMobil to Release Second Quarter 2026 Financial ResultsCompanies: ExxonMobilSPRING, Texas--ExxonMobil Holdings Corporation (NYSE: XOM) will release its second quarter 2026 financial results on Friday, July 31, 2026. The company will issue a press release via Business Wire that will be available at 5:30 a.m. CT at investor.exxonmobil.com . Darren Woods, Chairman and Chief Executive Officer; Neil Hansen, Senior Vice President and Chief Financial Officer; and Jim Chapman, Vice
- ExxonMobilExxonMobil Announces Planned Effective Date for Move to TexasCompanies: ExxonMobilSPRING, Texas--Exxon Mobil Corporation today announced that its redomiciliation from New Jersey to Texas is expected to become effective on July 1, 2026. As part of this change, ExxonMobil Holdings Corporation will become the publicly traded parent company, replacing Exxon Mobil Corporation of New Jersey. Shares will continue to trade on the New York Stock Exchange under the ticker symbol “XOM,” and